Pupillary changes as a potential biomarker for escitalopram in relation to CYP2C19 polymorphism

Trial Profile

Pupillary changes as a potential biomarker for escitalopram in relation to CYP2C19 polymorphism

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Anxiety disorders; Depression; Depressive disorders
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 01 Sep 2009 Results have been published in the European Journal of Clinical Pharmacology.
    • 12 Jul 2009 Results presented at 9th Congress of the European Association for Clinical Pharmacology and Therapeutics.
    • 05 Feb 2008 Status changed from initiated to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top